Citigroup Increases Gilead Sciences (NASDAQ:GILD) Price Target to $156.00

Gilead Sciences (NASDAQ:GILD) had its target price upped by investment analysts at Citigroup from $140.00 to $156.00 in a research report issued on Tuesday, Marketbeat Ratings reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s target price suggests a potential upside of 11.63% from the stock’s previous close.

GILD has been the topic of several other research reports. Wells Fargo & Company raised their target price on Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. Royal Bank Of Canada raised their price objective on shares of Gilead Sciences from $100.00 to $103.00 and gave the stock a “sector perform” rating in a report on Tuesday, January 20th. Needham & Company LLC upped their target price on shares of Gilead Sciences from $133.00 to $140.00 and gave the company a “buy” rating in a report on Thursday, November 13th. TD Cowen increased their target price on shares of Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Finally, Scotiabank started coverage on shares of Gilead Sciences in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $135.16.

Gilead Sciences Stock Up 1.4%

NASDAQ GILD traded up $1.96 on Tuesday, hitting $139.74. 809,147 shares of the stock were exchanged, compared to its average volume of 7,095,554. Gilead Sciences has a fifty-two week low of $93.37 and a fifty-two week high of $140.57. The company has a 50-day moving average price of $124.25 and a 200-day moving average price of $118.88. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The company has a market cap of $173.38 billion, a PE ratio of 21.57, a PEG ratio of 0.71 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period in the previous year, the company earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Sell-side analysts anticipate that Gilead Sciences will post 7.95 EPS for the current fiscal year.

Insider Activity at Gilead Sciences

In other news, EVP Deborah H. Telman sold 53,646 shares of Gilead Sciences stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total value of $6,590,411.10. Following the sale, the executive vice president owned 43,676 shares of the company’s stock, valued at $5,365,596.60. The trade was a 55.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Daniel Patrick O’day sold 115,640 shares of the stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the transaction, the chief executive officer directly owned 566,698 shares of the company’s stock, valued at $76,504,230. This represents a 16.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 247,397 shares of company stock worth $31,986,612 in the last 90 days. Corporate insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Norges Bank acquired a new stake in shares of Gilead Sciences in the second quarter worth approximately $2,150,268,000. Ameriprise Financial Inc. boosted its holdings in shares of Gilead Sciences by 397.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock valued at $748,147,000 after purchasing an additional 5,392,191 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Gilead Sciences by 3,763.8% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock valued at $518,368,000 after buying an additional 4,113,999 shares during the period. Invesco Ltd. increased its holdings in shares of Gilead Sciences by 33.5% during the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after buying an additional 3,394,330 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its position in shares of Gilead Sciences by 164.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock worth $387,286,000 after buying an additional 2,169,266 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.